Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASCO & EHA 2024 AML Highlights
27 June 2024 | Virtual Meeting
Presentation summaries of key AML abstracts from ASCO & EHA 2024 featuring panel discussions with leading experts
The Post-ASCO & EHA 2024 AML Highlights was supported by Genentech. Supporters have no influence over the production of content.
Updates in transplantation
Pre- allo-SCT flow cytometry testing for AML pts in first CR
Firas El Chaer University of Virginia, Charlottesville, VA, United States
allo-SCT from haplo donors with TBI vs. chemo for AML in first remission
Enrico Maffini IRCCS AOU di Bologna, Bologna, Italy
Session 1 panel discussion
Advances with menin inhibitors
Beat AML: AZA + VEN + revumenib for NPM1m or KMT2A AML
Joshua Zeidner UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NY, United States
JNJ-75276617 + VEN-AZA in R/R AML with KMT2A/NPM1 mut.
Andrew Wei Alfred Hospital and Monash University, Melbourne, Australia
DSP-5336 in patients with relapsed or refractory acute leukemia: Updated results from dose escalation
Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Session 2 panel discussion
Optimizing risk stratification in AML
LLS 2024 ELN-refined risk strat. in older adults w. ND AML
Fieke Hoff UT Southwestern Medical Center, Dallas, TX, United States
Adverse prognostic impact of secondary-type mutations in favorable risk AML
Dimitrios Kotsos Erasmus MC, Rotterdam, Netherlands
Session 3 panel discussion
Additional advances in AML management
Olutasidenib for mutated IDH1 AML
Jorge Cortes Georgia Cancer Center, Augusta University, Augusta, GA, United States
APOLLO: ATO + ATRA vs AIDA for ND, HR-APL
Uwe Platzbecker University Hospital Carl Gustav Carus, Dresden, Germany
FLAG-IDA + VEN in ND or R/R AML
Courtney DiNardo The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Session 4 panel discussion
Enduring Content Supported by:
Silver Supporter
